California, August 27, 2025
News Summary
Kite, a California-based biopharmaceutical company, has finalized a $350 million deal to acquire Interius BioTherapeutics, enhancing its development of in vivo CAR therapeutics for cancer treatment. The integration will see Interius’s operations merged into Kite’s research team, creating a new center of excellence in Philadelphia focused on advancing in vivo therapies. This strategic acquisition aims to streamline cancer treatments and improve patient outcomes, with anticipated implications for Gilead’s earnings in 2025.
California
Kite, a global biopharmaceutical company based in California and a subsidiary of Gilead Sciences Inc., has signed a definitive agreement to acquire Philadelphia-based Interius BioTherapeutics for $350 million. This strategic move aims to enhance Kite’s development of in vivo CAR therapeutics, which are pivotal in advancing cancer treatments.
This acquisition will see Kite take over all of Interius’ outstanding share capital, which is set to be payable at the time of closing. Following the transaction, Interius’s operations and workforce will be integrated into Kite’s research team, establishing a dedicated center of excellence in Philadelphia that will focus on the development of next-generation in vivo therapies.
According to Phil Johnson, President and CEO of Interius, this acquisition represents a significant milestone for the future of in vivo therapy, with the objective of reducing treatment timelines while simultaneously improving patient outcomes. Interius BioTherapeutics has pioneered an in vivo platform that enables the generation of ex vivo chimeric antigen receptor (CAR) T-cells directly within a patient’s body by inserting DNA into the patient’s genome. This innovative approach stands in contrast to traditional CAR T therapies, which typically require the harvesting, engineering, and reinfusion of cells, thereby streamlining the treatment process.
The modular architecture of Interius’s platform has the potential to adapt quickly across various disease states, which can significantly increase patient access to cell therapies, particularly for those with rapidly progressing diseases. Cindy Perettie, Executive Vice President of Kite, indicated that by merging Interius’s cutting-edge platform with Kite’s extensive expertise, the company aims to expedite advancements in in vivo therapies more efficiently.
This acquisition comes at a crucial time, with Kite declaring that the $350 million cash payment will be subject to customary adjustments. However, analysts project that this deal could impact Gilead’s GAAP and non-GAAP earnings per share (EPS) by approximately $0.23 to $0.25 in 2025. The completion of the transaction is dependent on meeting conditions set forth in the Hart-Scott-Rodino Antitrust Improvements Act, as well as other customary stipulations.
Kite is renowned for its substantial contributions to the field of cell therapy, having treated a higher number of patients with CAR T-cell therapy than any other organization globally. Meanwhile, Gilead Sciences has a long history of achieving breakthroughs in medicine spanning over three decades, serving patients in over 35 countries. Interius BioTherapeutics is recognized for its work in creating targeted, programmable vectors designed for the precise delivery of genetic medicines aimed at a variety of complex diseases.
Next Steps for Kite and Interius
The integration process following the acquisition will focus on leveraging the strengths of both companies to drive innovation in cancer treatment options. By building on Interius’s established framework for in vivo therapies, Kite aims to push the boundaries of what’s possible in cell therapy, aiming for treatments that are more accessible and effective for patients in need.
Market Considerations
Investors are closely watching this acquisition, given its implications on Gilead’s financial outlook and Kite’s ongoing role in the competitive biopharmaceutical landscape. The anticipated advancements in CAR therapy and in vivo approaches may bolster Kite’s position as a leader in the market, particularly as the demand for effective cancer therapies continues to rise.
Summary of Key Information:
- Acquisition cost: $350 million
- Companies involved: Kite and Interius BioTherapeutics
- Main focus: Development of in vivo CAR T-cell therapies
- Expected EPS impact: $0.23-$0.25 reduction in 2025
- Location of new center: Philadelphia
FAQ
What is the purpose of Kite acquiring Interius BioTherapeutics?
The acquisition aims to enhance Kite’s development of in vivo CAR therapeutics, which can potentially reduce treatment timelines and improve patient outcomes.
How much is Kite paying for Interius BioTherapeutics?
Kite is acquiring Interius for $350 million.
What is the significance of in vivo therapies in cancer treatment?
In vivo therapies have the potential to enable more streamlined treatment processes by allowing for the generation of CAR T-cells directly within the patient’s body, which can increase access to these therapies.
How will this acquisition affect Gilead’s earnings?
The acquisition is expected to reduce Gilead’s GAAP and non-GAAP EPS by approximately $0.23-$0.25 in 2025.
What role does Kite play in cell therapy?
Kite is recognized as a leader in the field of cell therapy and has treated more patients with CAR T-cell therapy than any other company.
Key Features of the Acquisition
| Feature | Description |
|---|---|
| Acquisition Value | $350 million in cash |
| Integration | Interius’s operations will be absorbed into Kite’s team |
| Location | New center of excellence to be established in Philadelphia |
| Technological Advancement | In vivo platform allows direct CAR T-cell generation in patients |
| Market Impact | Expected EPS impact of $0.23 to $0.25 in 2025 |
Deeper Dive: News & Info About This Topic
- Business Wire: Kite to Acquire Interius BioTherapeutics
- Wikipedia: CAR T cell therapy
- Penn Biz Report: California Company to Purchase Interius Biotherapeutics
- Reuters: Gilead Unit to Acquire Interius
- GlobeNewswire: Interius BioTherapeutics Presentation
Author: STAFF HERE BEVERLY HILLS WRITER
The Beverly Hills Staff Writer represents the experienced team at HEREBeverlyHills.com, your go-to source for actionable local news and information in Beverly Hills, Los Angeles County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the Rodeo Drive Concours d'Elegance, the Beverly Hills artSHOW, Concerts on Canon, and holiday celebrations throughout the city. Our coverage extends to key organizations like the Beverly Hills Chamber of Commerce and Visit Beverly Hills, plus leading businesses in luxury fashion, hospitality, and entertainment that drive the local economy. As part of the broader HERE network, including HERELosAngeles.com, HERESantaAna.com, HEREHuntingtonBeach.com, and HERECostaMesa.com, we provide comprehensive, credible insights into Southern California's dynamic landscape.
